BR112013030432A2 - método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos - Google Patents
método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidosInfo
- Publication number
- BR112013030432A2 BR112013030432A2 BR112013030432A BR112013030432A BR112013030432A2 BR 112013030432 A2 BR112013030432 A2 BR 112013030432A2 BR 112013030432 A BR112013030432 A BR 112013030432A BR 112013030432 A BR112013030432 A BR 112013030432A BR 112013030432 A2 BR112013030432 A2 BR 112013030432A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treating
- mps
- preparing
- lysosomal
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 13
- 230000002132 lysosomal effect Effects 0.000 title abstract 7
- 102000004190 Enzymes Human genes 0.000 title abstract 6
- 108090000790 Enzymes Proteins 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 208000015439 Lysosomal storage disease Diseases 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 3
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 208000015872 Gaucher disease Diseases 0.000 title abstract 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 238000002641 enzyme replacement therapy Methods 0.000 title abstract 2
- 201000004502 glycogen storage disease II Diseases 0.000 title abstract 2
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 title abstract 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 title 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 title 1
- 201000008333 alpha-mannosidosis Diseases 0.000 title 1
- 239000003431 cross linking reagent Substances 0.000 abstract 5
- 101150002416 Igf2 gene Proteins 0.000 abstract 4
- 239000000562 conjugate Substances 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 239000004971 Cross linker Substances 0.000 abstract 1
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 abstract 1
- 230000004700 cellular uptake Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 abstract 1
- 239000000863 peptide conjugate Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
resumo método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, ?-manosidose, e wohlman, sequência de dna e sequência de aminoácidos são descritos aqui métodos para preparar peptídeos conjugados alvos para enzimas lisossomais recombinantes através da modificação do (n)-terminal amino e um ou mais resíduos de lisina nas enzimas lisossomais humanas recombinantes usando um primeiro agente reticulante para obter enzimas lisossomal humana recombinante modificada pelo primeiro agente reticulante, modificando o primeiro aminoácido dentro de um ligante curto no (n)-terminal amino em um peptídeo igf-2 variante usando um segundo agente reticulante para obter um peptídeo igf-2 variante modificado pelo segundo agente reticulante, e então conjugar a enzima lisossomal humana recombinante modificada pelo primeiro agente reticulante ao peptídeo igf-2 variante modificado pelo segundo agente reticulante contendo um ligante curto. também são descritos aqui os conjugados sintetizados caracterizados como tendo afinidade maior para o receptor igf2/ci-mpr e absorção celular usando os métodos descritos aqui. são descritos ainda, métodos para tratamento usando os conjugados descritos. 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490957P | 2011-05-27 | 2011-05-27 | |
PCT/US2012/039705 WO2012166653A2 (en) | 2011-05-27 | 2012-05-25 | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013030432A2 true BR112013030432A2 (pt) | 2016-12-13 |
Family
ID=47260229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013030432A BR112013030432A2 (pt) | 2011-05-27 | 2012-05-25 | método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos |
Country Status (20)
Country | Link |
---|---|
US (2) | US9545450B2 (pt) |
EP (1) | EP2714752B1 (pt) |
JP (2) | JP6300720B2 (pt) |
KR (2) | KR101955054B1 (pt) |
CN (2) | CN104160033B (pt) |
BR (1) | BR112013030432A2 (pt) |
CA (1) | CA2836318C (pt) |
CY (1) | CY1120485T1 (pt) |
DK (1) | DK2714752T3 (pt) |
ES (1) | ES2660185T3 (pt) |
HR (1) | HRP20180291T1 (pt) |
HU (1) | HUE038172T2 (pt) |
LT (1) | LT2714752T (pt) |
NO (1) | NO2820016T3 (pt) |
PL (1) | PL2714752T3 (pt) |
PT (1) | PT2714752T (pt) |
RS (1) | RS56913B1 (pt) |
SI (1) | SI2714752T1 (pt) |
TR (1) | TR201802230T4 (pt) |
WO (1) | WO2012166653A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925303B2 (en) | 2012-11-13 | 2018-03-27 | Edwards Lifesciences Corporation | Methods for cross-linking bioprosthetic tissue using bio-orthogonal binding pairs |
MX2015012873A (es) * | 2013-03-15 | 2016-02-03 | Amicus Therapeutics Inc | Reticuladores quimicos. |
CN106414485A (zh) * | 2014-04-04 | 2017-02-15 | 韦斯塔隆公司 | 人工活化的毒性肽 |
WO2016025519A1 (en) * | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
EA038986B1 (ru) * | 2014-09-30 | 2021-11-18 | Амикус Терапьютикс, Инк. | Высокоактивная кислая альфа-глюкозидаза с повышенным содержанием углеводов |
CN104356238B (zh) * | 2014-10-15 | 2018-01-09 | 大连理工大学 | 一种重组蛋白a亲和配基的定点固定化方法 |
JP6700298B2 (ja) * | 2015-03-11 | 2020-05-27 | オーシーヴィー インテレクチュアル キャピタル リミテッド ライアビリティ カンパニー | 繊維材料でマフラーを充填する方法及びシステム |
JP2018538008A (ja) | 2015-11-06 | 2018-12-27 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム酵素の取り込みを中和する抗体または他の因子の検出のための細胞ベースアッセイ |
HUE052155T2 (hu) * | 2015-12-08 | 2021-04-28 | Regeneron Pharma | Enzimek internalizálására szolgáló készítmények és módszerek |
AU2018281280A1 (en) | 2017-06-07 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
KR20200018483A (ko) | 2017-06-14 | 2020-02-19 | 비로메틱스 아게 | 호흡기 합포체 바이러스에 대한 방어를 위한 고리형 펩티드 |
JP2021500857A (ja) | 2017-10-02 | 2021-01-14 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 酵素補充療法用酵素を含む融合タンパク質 |
US11492610B2 (en) | 2018-03-08 | 2022-11-08 | California Institute Of Technology | Sample multiplexing for single-cell RNA sequencing |
AU2019261982A1 (en) | 2018-04-30 | 2020-10-15 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
BR112021006829A2 (pt) | 2018-10-10 | 2021-07-20 | Amicus Therapeutics, Inc. | composições de polipeptídeos estabilizados com ligações dissulfeto e métodos de uso |
US20220023434A1 (en) | 2018-12-19 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods |
CN113260377A (zh) | 2018-12-20 | 2021-08-13 | 维罗米蒂克斯股份公司 | 脂肽构建块和合成病毒样颗粒 |
AU2020266552A1 (en) * | 2019-04-30 | 2021-11-11 | Amicus Therapeutics, Inc. | Compositions useful for treatment of Pompe disease |
CN110373405B (zh) * | 2019-07-24 | 2023-12-15 | 杭州恩和生物科技有限公司 | 一种接枝聚合物的生物酶及其制备方法和固定方法 |
JP2022552254A (ja) * | 2019-10-10 | 2022-12-15 | アミカス セラピューティックス インコーポレイテッド | バリアントigf2構築体 |
US20230355737A1 (en) | 2020-09-28 | 2023-11-09 | Dbv Technologies | Particle comprising an rsv-f protein for use in rsv vaccination |
US20240024507A1 (en) | 2020-12-01 | 2024-01-25 | The Trustees Of The University Of Pennsylvania | Novel compositions with tissue-specific targeting motifs and compositions containing same |
MX2023012513A (es) | 2021-04-23 | 2023-12-15 | Univ Pennsylvania | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen. |
WO2024130067A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1118334A1 (en) * | 2000-01-11 | 2001-07-25 | Aventis Behring Gesellschaft mit beschränkter Haftung | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20030072761A1 (en) * | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
ES2830350T3 (es) | 2008-05-07 | 2021-06-03 | Biomarin Pharm Inc | Péptidos de dirección lisosómica y usos de los mismos |
CN102448494B (zh) * | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
-
2012
- 2012-05-25 KR KR1020137034111A patent/KR101955054B1/ko active IP Right Grant
- 2012-05-25 WO PCT/US2012/039705 patent/WO2012166653A2/en active Application Filing
- 2012-05-25 PT PT127930154T patent/PT2714752T/pt unknown
- 2012-05-25 CN CN201280037051.0A patent/CN104160033B/zh active Active
- 2012-05-25 PL PL12793015T patent/PL2714752T3/pl unknown
- 2012-05-25 JP JP2014513625A patent/JP6300720B2/ja active Active
- 2012-05-25 HU HUE12793015A patent/HUE038172T2/hu unknown
- 2012-05-25 ES ES12793015.4T patent/ES2660185T3/es active Active
- 2012-05-25 LT LTEP12793015.4T patent/LT2714752T/lt unknown
- 2012-05-25 CN CN201810440498.1A patent/CN108586621A/zh not_active Withdrawn
- 2012-05-25 RS RS20180188A patent/RS56913B1/sr unknown
- 2012-05-25 BR BR112013030432A patent/BR112013030432A2/pt not_active Application Discontinuation
- 2012-05-25 SI SI201231229T patent/SI2714752T1/en unknown
- 2012-05-25 DK DK12793015.4T patent/DK2714752T3/en active
- 2012-05-25 EP EP12793015.4A patent/EP2714752B1/en active Active
- 2012-05-25 CA CA2836318A patent/CA2836318C/en active Active
- 2012-05-25 US US14/122,858 patent/US9545450B2/en active Active
- 2012-05-25 TR TR2018/02230T patent/TR201802230T4/tr unknown
- 2012-05-25 KR KR1020197005833A patent/KR20190022943A/ko not_active Application Discontinuation
-
2013
- 2013-02-25 NO NO13708603A patent/NO2820016T3/no unknown
-
2016
- 2016-11-09 US US15/347,006 patent/US10660972B2/en active Active
-
2017
- 2017-07-07 JP JP2017133655A patent/JP2017225444A/ja active Pending
-
2018
- 2018-02-16 HR HRP20180291TT patent/HRP20180291T1/hr unknown
- 2018-02-22 CY CY20181100212T patent/CY1120485T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR101955054B1 (ko) | 2019-03-07 |
HRP20180291T1 (hr) | 2018-03-23 |
WO2012166653A2 (en) | 2012-12-06 |
WO2012166653A3 (en) | 2014-05-01 |
RS56913B1 (sr) | 2018-05-31 |
EP2714752A4 (en) | 2015-08-26 |
CA2836318C (en) | 2018-11-27 |
KR20140033155A (ko) | 2014-03-17 |
NO2820016T3 (pt) | 2017-12-30 |
US9545450B2 (en) | 2017-01-17 |
JP2014518063A (ja) | 2014-07-28 |
US20140302001A1 (en) | 2014-10-09 |
CA2836318A1 (en) | 2012-12-06 |
PT2714752T (pt) | 2018-02-26 |
US10660972B2 (en) | 2020-05-26 |
CN108586621A (zh) | 2018-09-28 |
CN104160033B (zh) | 2018-06-01 |
TR201802230T4 (tr) | 2018-03-21 |
US20170319710A1 (en) | 2017-11-09 |
KR20190022943A (ko) | 2019-03-06 |
CN104160033A (zh) | 2014-11-19 |
PL2714752T3 (pl) | 2018-04-30 |
ES2660185T3 (es) | 2018-03-21 |
EP2714752A2 (en) | 2014-04-09 |
HUE038172T2 (hu) | 2018-09-28 |
LT2714752T (lt) | 2018-03-12 |
CY1120485T1 (el) | 2019-07-10 |
JP6300720B2 (ja) | 2018-03-28 |
SI2714752T1 (en) | 2018-03-30 |
EP2714752B1 (en) | 2017-11-22 |
DK2714752T3 (en) | 2018-02-26 |
JP2017225444A (ja) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013030432A2 (pt) | método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos | |
AU2017312113B2 (en) | Nucleic acid products and methods of administration thereof | |
AU2016218977C1 (en) | Nucleic acid products and methods of administration thereof | |
US9803185B2 (en) | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein | |
JP2015517995A (ja) | 美容タンパク質およびペプチドの産生のための修飾ポリヌクレオチド | |
CN101475643B (zh) | 一种双单链抗体强化融合蛋白dFv-LDP-AE及其制备方法和应用 | |
WO2014082080A3 (en) | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases | |
AU2014252666B2 (en) | Use of antibody-urease conjugates for diagnostic and therapeutic purposes | |
CN107226858A (zh) | 干扰素高分子结合体ifn-pmpc的制备及其应用 | |
Ramirez-Paz et al. | Site-specific PEGylation crosslinking of L-asparaginase subunits to improve its therapeutic efficiency | |
RU2607527C2 (ru) | Ковалентный моноконъюгат полиэтиленгликоля с тимозином бета 4, устойчивый к деградации в токе крови, и способ его получения | |
WO2015009596A3 (en) | Methods and oral formulations for enzyme replacement therapy of human lysosomal and metabolic diseases | |
JP2021533201A (ja) | Peg化破傷風神経毒素および筋緊張低下の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: AMICUS THERAPEUTICS, INC. (US) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |